We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Annual Growth of POC Tests Forecast at Six Percent

By LabMedica International staff writers
Posted on 24 Dec 2012
The USD 16.7 billion market for point of care (POC) testing is expected to grow at the rate of 6 percent a year, slightly higher than the in vitro diagnostics market as a whole. More...
In the late 1990s, the POC diagnostic market was expected to grow at a rate of 15% to 20% per year. While it has grown and is now a significant segment of the overall in vitro diagnostic (IVD) market, the rapid growth rates originally expected were not achieved.

POC testing includes in vitro diagnostic (IVD) tests performed by the patients themselves, such as glucose monitoring, pregnancy tests, and cholesterol tests, as well as tests performed at physicians’ offices, clinics and other patient care centers. Kalorama's analysis does not include tests sent to a central laboratory for processing. Much of the POC testing is carried out for glucose monitoring although in some cases coagulation and infectious disease testing can also be performed at the POC.

A Kalorama Information (New York, NY, USA) report authored by Sannes & Associates indicated that, “Growth in POC testing is being fueled by chronic diseases, the globalization of infectious diseases, and the associated public health issues. Advances in therapies are giving physicians more tools for the treatment of patients if they are able to rapidly diagnose the problem, which is helping to make the case for POC test purchases and investment in companies that provide them.”

The report contains a detailed segment breakdown of revenues, profiles of companies in the market, and a discussion of trends. New POC innovations are also detailed in the report.

The Kalorama report lists 140 companies that currently market POC tests, plus over 40 companies that are developing POC technologies and products. Companies profiled in the report use a wide range of different technologies to develop and market rapid tests for use at POC. These include a large number of IVD tests that are performed today only in centralized laboratories.

Related Links:

Kalorama Information



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.